Trial · NCT00121108
Results by group52
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 52
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Respiratory Syncytial Virus (RSV) Hospitalization | Placebo | 80 | Participants | ||
| Number of Participants With Respiratory Syncytial Virus (RSV) Hospitalization | Motavizumab | 21 | Participants | ||
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) | Placebo | TEAEs | 686 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) | Motavizumab | TEAEs | 1361 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) | Placebo | TESAEs | 148 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) | Motavizumab | TESAEs | 212 | Participants | |
| Number of Participants With RSV Outpatient Medically Attended Lower Respiratory Illness (MA LRI) | Placebo | 71 | Participants | ||
| Number of Participants With RSV Outpatient Medically Attended Lower Respiratory Illness (MA LRI) | Motavizumab | 41 | Participants | ||
| Number of Participants With Medically Attended-Otitis Media (MA-OM) Events | Placebo | 275 | Participants | ||
| Number of Participants With Medically Attended-Otitis Media (MA-OM) Events | Motavizumab | 532 | Participants | ||
| Number of Participants With Frequency of MA-OM Events | Placebo | MA OM: 0 | 435 | Participants | |
| Number of Participants With Frequency of MA-OM Events | Motavizumab | MA OM: 0 | 885 | Participants | |
| Number of Participants With Frequency of MA-OM Events | Placebo | MA OM: 1 | 190 | Participants | |
| Number of Participants With Frequency of MA-OM Events | Motavizumab | MA OM: 1 | 372 | Participants | |
| Number of Participants With Frequency of MA-OM Events | Placebo | MA OM: 2 | 55 | Participants | |
| Number of Participants With Frequency of MA-OM Events | Motavizumab | MA OM: 2 | 114 | Participants | |
| Number of Participants With Frequency of MA-OM Events | Placebo | MA OM: 3 | 26 | Participants | |
| Number of Participants With Frequency of MA-OM Events | Motavizumab | MA OM: 3 | 32 | Participants | |
| Number of Participants With Frequency of MA-OM Events | Placebo | MA OM: >3 | 4 | Participants | |
| Number of Participants With Frequency of MA-OM Events | Motavizumab | MA OM: >3 | 14 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00121108/results